Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM1907-05 for preventive treatment of latent tuberculosis infection (Phase 3, China)
ChiCTR2000035662Phase 3Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SIM1907-05 in latent tuberculosis infection (LTBI) (2 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoints: Cumulative incidence of active tuberculosis within 2 years and Treatment completion rate. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
SIM1907-05
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ChiCTR2000035662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035662.